Protective effect of melatonin in a chronic experimental model of Parkinson's disease

Brain Research

Volumn 943, Issue 2, 2002, Pages 163-173

  Antolín, Isaac ^a   Mayo, Juan Carlos ^a   Sainz, Rosa María ^a,b   Del Brío, María De Los Angeles ^a   Herrera, Federico ^a   Martín, Vanesa ^a   Rodríguez, Carmen ^a,b  

^a UNIVERSIDAD DE OVIEDO   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); Chronic experimental model; Melatonin; Mice; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIOXIDANT; FREE RADICAL; MELATONIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG PENETRATION; ENZYME ASSAY; EXPERIMENTAL MODEL; MALE; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TISSUE LEVEL; TREATMENT OUTCOME; ULTRASTRUCTURE;

ANIMALS; AXONS; CELL DEATH; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FREE RADICAL SCAVENGERS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MELATONIN; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON; NEURONS; NEUROPROTECTIVE AGENTS; OLIGODENDROGLIA; ORGANELLES; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA;

EID: 0037067791     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)02551-9     Document Type: Article

References (58)

1. Acuña-Castroviejo D., Coto-Montes A., Gaia Monti M., Ortiz G.G., Reiter R.J. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci. 60:1997;PL23-PL29.
2. Acuña-Castroviejo D., Martín M., Macías M., Escames G., León J., Khaldy H., Reiter R.J. Melatonin, mitochondria, and cellular bioenergetics. J. Pineal Res. 30:2001;65-74.
3. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69:1997;1326-1329.
4. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Camis N., Mersden C.D., Jenner P., Halliwell B. Oxidative DNA damage in the Parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69:1997;1196-1203.
5. Arai N., Misugi K., Goshima Y., Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res. 515:1990;57-63.
6. Ben-Shachar D., Youdim M.B.H. Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction. J. Neural Transm. 29:1990;251-258.
7. Bezard E., Dovero S., Bioulac B., Gross C.E. Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neurosci. Lett. 334:1997;47-50.
8. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
9. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA. 80:1983;4546-4550.
10. Cassone V.M. Effect of melatonin on vertebrate circadian systems. Trends Neurosci. 13:1990;457-464.
11. Cochiolo J.A., Ehsanian R., Bruck D.K. Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: evidence of compensatory plasticity in nigrostriatal neurons. J. Neurosci. Res. 59:2000;126-135.
12. Costa E.J.X., López R.H., Lamy-Freund M.T. Permeability of pure lipid bilayers to melatonin. J. Pineal Res. 19:1995;123-126.
13. Cruz-Sanchez F.F., Cardozo A., Ambrosio S., Tolosa D., Mahy N. Plasticity of the nigrostriatal system in MPTP-treated mice. A biochemical and morphological correlation. Mol. Chem. Neuropathol. 19:1993;163-176.
14. Cui J., Holmes E.H., Greene T.G., Liu P.K. Oxidative DNA damage precedes DNA fragmentation after experimental stroke in rat brain. FASEB J. 14:2000;955-967.
15. Dabeni-Sala F., Di Santo S., Franceschini D., Skaper S.D., Giusti P. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J. 15:2001;164-170.
16. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., Kopin I.J. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1:1979;249-254.
17. Dawson D., Encel N. Melatonin and sleep in humans. J. Pineal Res. 15:1993;1-12.
18. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1989;1830-1836.
19. Ferraro T.N., Golden G.T., DeMattei M., Hare T.A., Farinello R.G. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse. Neuropharmacology. 25:1986;1071-1074.
20. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol. 119:1992;493-501.
21. Hallman H., Lange J., Olson L., Stromberg I., Jonsson G. Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. J. Neurochem. 44:1985;117-127.
22. Hayakawa M., Katsumata K., Yoneda M., Tanaka M., Sugiyama S., Ozawa T. Age-related extensive fragmentation of mitochondrial DNA into minicircles. Biochem. Biophys. Res. Commun. 226:1996;369-377.
23. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
24. Hung H.C., Lee E.H. MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways. Free Radic. Biol. Med. 24:1998;76-84.
25. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 4:1995;257-269.
26. Jellinger K.A., Stadelmann C.H. The enigma of cell death in neurodegenerative disorders. J. Neural Transm. Suppl. 60:2000;21-36.
27. Joo W.S., Jin B.K., Park C.W., Maeng S.H., Kim Y.S. Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats. Neuroreport. 9:1998;4123-4126.
28. Langston J.W., Ballard P., Tetrud F.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
29. Lees A.J. When did Ray Kennedy's Parkinson's disease begin? Mov. Disord. 7:1992;110-116.
30. Lewandowska E., Kurkowska-Jastrzebska I., Lechowicz W., Czlonkowska A., Czlonkowski A. Ultrastructural changes in substantia nigra and striatum observed in a mouse model of Parkinson's disease induced by MPTP administration. Folia Neuropathol. 37:1999;239-242.
31. Lezoualc'h F.H., Skutella F., Widmann M., Behl C. Melatonin prevents oxidative stress induced cell death in hippocampal cells. Neuroreport. 7:1996;2071-2077.
32. Maxwell W.L. Cellular responses to ischaemic CNS injury. Berry M., Logan A. CNS Injuries: Cellular Responses and Pharmacological Strategies. 1999;19-42 CRC Press, Boca Raton, FL.
33. Mayo J.C., Sainz R.M., Uría H., Antolín I., Esteban M.M., Rodríguez C. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease. J. Pineal Res. 24:1998;179-192.
34. Menéndez-Peláez A., Poeggeler B., Reiter R.J., Barlow-Walden L.R., Pablos M.I., Tan D.X. Nuclear localization of melatonin in different mammalian tissues: immunocytochemical and radioimmunoassay evidence. J. Cell. Biochem. 53:1993;373-382.
35. Mitsumoto Y., Watanabe A., Mori A., Koga N. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem. Biophys. Res. Commun. 248:1998;660-663.
36. Mochizuki H., Mori H., Mizuno Y. Apoptosis in neurodegenerative disorders. J. Neural Transm. Suppl. 50:1997;125-140.
37. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4 phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
38. Ortiz G.G., Crespo-López M.E., Moran-Moguel C., Garcia J.J., Reiter R.J., Acuña-Castroviejo D. Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuroendocrinol. Lett. 22:2001;101-108.
39. Ozawa T., Hayakawa M., Katsumate K., Yoneda M. Fragile mitochondrial DNA: the missing link in the apoptotic neuronal cell death in Parkinson's disease. Biochem. Biophys. Res. Commun. 235:1997;158-161.
40. Pappert E.J., Tangney C.C., Goetz C.G., Ling Z.D., Lipton J.W., Stebbins G.T., Carvey P.M. Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology. 47:1996;1037-1042.
41. Pappolla M., Sos M., Omar R.A., Bick R.J., Hickson-Bick D.L., Reiter R.J., Efthimiopoulos S., Robakis N.K. Melatonin prevents death of neuroblastoma cells exposed to Alzheimer's amyloid peptide. J. Neurosci. 17:1997;1683-1690.
42. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328:1993;176-183.
43. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann. Neurol. 39:1996;37-45.
44. Perry T.L., Young R.S. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67:1986;269-274.
45. Reiter R.J. Melatonin: that ubiquitously acting pineal hormone. News Physiol. Sci. 6:1991;223-227.
46. Reiter R.J. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J. 9:1995;526-533.
47. Reiter R.J. Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol. 56:1998;359-384.
48. Rodríguez C., Sainz R.M., Mayo J.C. Neurotoxicity by L-dopa and dopamine: neuroprotective role of melatonin. Segura-Aguilar J. Mechanisms of Degeneration and Protection of the Dopaminergic System. 2001;239-275 FP Graham Publishing Co. Johnson City, Tennesse.
49. Saggu H., Cooksey J., Dexter D., Wells F.R., Lees A., Jenner P., Marsden C.D. A selective increase in particulate superoxide dismutase activity in Parkinsonian substantia nigra. J. Neurochem. 53:1989;692-697.
50. Schneider J.S., Denaro F.J. Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. J. Neuropathol. Exp. Neurol. 47:1988;452-458.
51. Shida C.S., Castrucci A.M.I., Lamy-Freund M.T. High melatonin solubility in aqueous medium. J. Pineal Res. 16:1994;198-201.
52. Sidman R.L., Angevine J.A., Pierce E.T. Atlas of the Mouse Brain and Spinal Cord, A Common Wealth Fund Book. 1971;Harvard University Press, Cambridge, MA.
53. Sonsalla P.K., Jochnowitz N.D., Zeevalk G.D., Oostveen J.A., Hall E.D. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res. 738:1996;172-175.
54. Tan D.-X., Poeggeler B., Reiter R.J., Chen C.D., Chen S., Manchester L.C., Barlow-Walden L.R. The pineal hormone melatonin inhibits DNA adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett. 70:1993;65-71.
55. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci. 20:2000;9207-9214.
56. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc. Natl. Acad. Sci. USA. 93:1996;2696-2701.
57. Zareba M., Bober A., Korytowski W., Zecca L., Sarna T. The effect of synthetic neuromelanin on yield of free hydroxyl radicals generated in model system. Biochem. Biophys. Acta. 1271:1995;343-348.
58. Zhang J., Graham D.G., Montine T.J., Ho Y.S. Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J. Neuropathol. Exp. Neurol. 59:2000;53-61.